DK3551664T3 - Antistoffer og polypeptider rettet mod cd127 - Google Patents

Antistoffer og polypeptider rettet mod cd127 Download PDF

Info

Publication number
DK3551664T3
DK3551664T3 DK17835592.1T DK17835592T DK3551664T3 DK 3551664 T3 DK3551664 T3 DK 3551664T3 DK 17835592 T DK17835592 T DK 17835592T DK 3551664 T3 DK3551664 T3 DK 3551664T3
Authority
DK
Denmark
Prior art keywords
polypeptides
aimed
antibodies
polypeptides aimed
Prior art date
Application number
DK17835592.1T
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Virginie Thepenier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Application granted granted Critical
Publication of DK3551664T3 publication Critical patent/DK3551664T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
DK17835592.1T 2016-12-09 2017-12-07 Antistoffer og polypeptider rettet mod cd127 DK3551664T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306655 2016-12-09
PCT/EP2017/081911 WO2018104483A1 (en) 2016-12-09 2017-12-07 Antibodies and polypeptides directed against cd127

Publications (1)

Publication Number Publication Date
DK3551664T3 true DK3551664T3 (da) 2021-05-03

Family

ID=57796143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17835592.1T DK3551664T3 (da) 2016-12-09 2017-12-07 Antistoffer og polypeptider rettet mod cd127

Country Status (39)

Country Link
US (3) US11098128B2 (da)
EP (1) EP3551664B1 (da)
JP (1) JP6986559B2 (da)
KR (1) KR102306366B1 (da)
CN (1) CN110392695B (da)
AR (1) AR110326A1 (da)
AU (1) AU2017373819B2 (da)
CA (1) CA3042582C (da)
CL (1) CL2019001530A1 (da)
CO (1) CO2019005909A2 (da)
CR (1) CR20190273A (da)
CY (1) CY1124153T1 (da)
DK (1) DK3551664T3 (da)
EA (1) EA201991005A1 (da)
ES (1) ES2867900T3 (da)
HR (1) HRP20210697T1 (da)
HU (1) HUE054206T2 (da)
IL (1) IL266837B (da)
LT (1) LT3551664T (da)
MA (1) MA49727B1 (da)
MD (1) MD3551664T2 (da)
MX (1) MX2019006577A (da)
MY (1) MY190770A (da)
NZ (1) NZ753213A (da)
PE (1) PE20191152A1 (da)
PH (1) PH12019501285B1 (da)
PL (1) PL3551664T3 (da)
PT (1) PT3551664T (da)
PY (1) PY1794093A (da)
RS (1) RS61808B1 (da)
RU (1) RU2769352C2 (da)
SA (1) SA519401906B1 (da)
SI (1) SI3551664T1 (da)
SM (1) SMT202100267T1 (da)
TW (1) TWI777996B (da)
UA (1) UA126386C2 (da)
UY (1) UY37511A (da)
WO (1) WO2018104483A1 (da)
ZA (1) ZA201902743B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3405491A1 (en) 2016-01-21 2018-11-28 VHsquared Limited Polypeptides
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3635410A4 (en) 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
JP7692844B2 (ja) * 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US11746139B2 (en) * 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN113501499A (zh) * 2021-08-11 2021-10-15 无锡贝塔医药科技有限公司 一种高纯无水溴化氘气体的制备方法及其应用
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
JP2025518164A (ja) 2022-05-30 2025-06-12 オセ イムノセラピューティクス Ｉｌ７ｒモジュレーター活性のバイオマーカー
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用
EP4455308A1 (en) 2023-04-24 2024-10-30 Les Laboratoires Servier Il-7r gene signatures
JP2026526546A (ja) * 2023-07-31 2026-08-07 キュー３２・バイオ・インコーポレーテッド アトピー性皮膚炎の治療
WO2025098341A1 (en) * 2023-11-10 2025-05-15 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
WO2026022216A1 (en) 2024-07-23 2026-01-29 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
WO2026062296A1 (en) 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r
WO2026132078A1 (en) 2024-12-17 2026-06-25 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of patients suffering from an inflammatory bowel disease and at high risk of relapse
WO2026159138A1 (en) * 2025-01-21 2026-07-30 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and tl1a or tnfrsf25
WO2026159136A1 (en) * 2025-01-21 2026-07-30 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and tnf-alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
RU2769352C2 (ru) 2022-03-30
HRP20210697T1 (hr) 2021-07-23
MA49727B1 (fr) 2021-05-31
IL266837B (en) 2020-06-30
SI3551664T1 (sl) 2021-08-31
SMT202100267T1 (it) 2021-07-12
PE20191152A1 (es) 2019-09-05
LT3551664T (lt) 2021-05-25
PH12019501285B1 (en) 2023-09-08
US20220332834A2 (en) 2022-10-20
EP3551664A1 (en) 2019-10-16
PT3551664T (pt) 2021-04-21
CR20190273A (es) 2019-10-17
US11926671B2 (en) 2024-03-12
CA3042582A1 (en) 2018-06-14
AR110326A1 (es) 2019-03-20
US20240352135A1 (en) 2024-10-24
SA519401906B1 (ar) 2022-12-20
US20190375844A1 (en) 2019-12-12
MX2019006577A (es) 2019-10-07
MA49727A (fr) 2019-10-16
ZA201902743B (en) 2025-11-26
CO2019005909A2 (es) 2019-07-31
RS61808B1 (sr) 2021-06-30
IL266837A (en) 2019-07-31
US20210395376A1 (en) 2021-12-23
CY1124153T1 (el) 2022-05-27
JP2020500542A (ja) 2020-01-16
AU2017373819B2 (en) 2022-03-31
CN110392695A (zh) 2019-10-29
RU2019115610A3 (da) 2021-04-05
CN110392695B (zh) 2021-02-02
AU2017373819A1 (en) 2019-05-30
PH12019501285A1 (en) 2019-12-16
PL3551664T3 (pl) 2021-08-02
NZ753213A (en) 2022-05-27
CL2019001530A1 (es) 2019-10-11
MY190770A (en) 2022-05-12
ES2867900T3 (es) 2021-10-21
UY37511A (es) 2018-06-29
KR20190090005A (ko) 2019-07-31
RU2019115610A (ru) 2021-01-12
UA126386C2 (uk) 2022-09-28
EP3551664B1 (en) 2021-02-17
EA201991005A1 (ru) 2019-12-30
US11098128B2 (en) 2021-08-24
JP6986559B2 (ja) 2022-01-05
PY1794093A (es) 2019-03-01
KR102306366B1 (ko) 2021-09-29
HUE054206T2 (hu) 2021-08-30
CA3042582C (en) 2023-05-23
TW201833137A (zh) 2018-09-16
TWI777996B (zh) 2022-09-21
BR112019010595A2 (pt) 2019-09-17
WO2018104483A1 (en) 2018-06-14
MD3551664T2 (ro) 2021-06-30

Similar Documents

Publication Publication Date Title
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
PL3551664T3 (pl) Przeciwciała i polipeptydy skierowane przeciwko cd127
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3390444T3 (da) Anti-tl1a-antigenbindende proteiner og anvendelser deraf
DK3468990T3 (da) Anti-C5-antistoffer og anvendelser deraf
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3347379T5 (da) Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3313884T3 (da) Anti-cd123-antistoffer og konjugater og derivater deraf
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil